Berlin-Chemie AG, a prominent player in the pharmaceutical industry, is headquartered in Berlin, Germany. Founded in 1890, the company has established a strong presence in various operational regions, particularly across Europe and Asia. Specialising in the development and production of prescription medicines, Berlin-Chemie focuses on therapeutic areas such as cardiology, oncology, and diabetes care. The company is renowned for its innovative approach to drug formulation, offering unique products that cater to the specific needs of patients and healthcare professionals. With a commitment to quality and research, Berlin-Chemie AG has achieved significant milestones, including numerous partnerships and collaborations that enhance its market position. As a subsidiary of the Menarini Group, Berlin-Chemie continues to expand its influence in the global pharmaceutical landscape, driven by a dedication to improving health outcomes.
How does Berlin-Chemie AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Berlin-Chemie AG's score of 20 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Berlin-Chemie AG, headquartered in Germany, currently does not provide specific carbon emissions data for recent years, as no emissions figures are available. Consequently, there are no documented Scope 1, 2, or 3 emissions to report. In the absence of concrete emissions data, it is essential to highlight the company's commitment to climate action and sustainability within the pharmaceutical industry. While specific reduction targets or initiatives have not been disclosed, Berlin-Chemie AG is likely to be aligning with broader industry standards and practices aimed at reducing carbon footprints and enhancing environmental responsibility. As the pharmaceutical sector increasingly focuses on sustainability, companies like Berlin-Chemie AG are expected to adopt measures that contribute to climate resilience and carbon neutrality in the future.
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Berlin-Chemie AG is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.